On pages 1039 and 1043 in the February 1, 2008, issue, the eighth author's last name, affiliation, and contributing author initials are incorrect. The correct name is Carlo Gambacorti-Passerini; the affiliation is S. Gerardo Hospital, University of Milano Bicocca, Monza, Italy; and the correct author initials in the Contribution paragraph of “Authorship” are C.G.-P. The errors were corrected in the online version, which now differs from the print version.
. 2008 Jul 15;112(2):452. doi: 10.1182/blood-2008-05-158873
Hochhaus et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood. 2008;111:1039-1043.
© 2008 by The American Society of Hematology
PMCID: PMC2464565
This corrects the article "Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment." in volume 111 on page 1039.
This corrects the article "Bcl-2–family proteins and hematologic malignancies: history and future prospects" in volume 111 on page 3322.
This corrects the article "EBV LMP2A affects LMP1-mediated NF-κB signaling and survival of lymphoma cells by regulating TRAF2 expression" in volume 111 on page 3813.